# Contents in Print

**Preface** ................................................................. ix

## QUALITY AND RELATED ISSUES

1. **Quality Management Systems: Principles and Practice** ........ 1
   *Eva D. Quinley, MS, MT(ASCP)SBB*
   - Background .................................................. 1
   - Concepts in Quality ...................................... 2
   - Quality Management Systems Approach ................. 4
   - Evaluation of the Quality Management System .......... 5
   - The Quality Management System in Practice .......... 6
   - Key Points .................................................. 23
   - References .................................................. 24
   - Appendix 1-1. Glossary of Commonly Used Quality Terms .. 26
   - Appendix 1-2. *Code of Federal Regulations* Quality-Related References ... 28
   - Appendix 1-3. Suggested Quality Control Performance Intervals for Equipment and Reagents ........................................... 29

2. **Facilities, Work Environment, and Safety** ...................... 33
   *J. Wade Atkins, MS, MT(ASCP)SBB, CQA(ASQ), and Leslie P. Taylor, CQA(ASQ)*
   - Facilities ................................................... 34
   - Safety Program ........................................... 36
   - Fire Prevention .......................................... 39
   - Electrical Safety .......................................... 40
   - Biosafety .................................................. 41
   - Chemical Safety ........................................... 49
   - Radiation Safety ........................................... 53
   - Shipping Hazardous Materials ............................ 56
   - General Waste Management ............................... 57
   - Key Points .................................................. 57
   - References .................................................. 58
   - Appendix 2-1. Safety Regulations and Recommendations Applicable to Health-Care Settings ........................................... 61
Appendix 2-3. Biosafety Level 2 Precautions ............................... 66
Appendix 2-4. Sample List of Hazardous Chemicals that May Be Encountered in a Blood Bank ................................. 67
Appendix 2-5. Chemical Categories and How to Work Safely with Them ... 69
Appendix 2-6. Incidental Spill Response ..................................... 71
Appendix 2-7. Managing Hazardous Chemical Spills .......................... 74

3. Regulatory Considerations in Transfusion Medicine and Cellular Therapies ......................................................... 77

Joseph Schwartz, MD, MPH, and Orieji Illoh, MD
FDA Oversight of Blood Establishments ..................................... 78
Medical Laboratory Laws and Regulations .................................. 84
Local Laws, Hospital Regulations, and Accreditation ......................... 85
Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) ................................................... 86
Key Points .................................................................................. 89
References ............................................................................... 90

4. National Hemovigilance: The Current State ................................. 93

Kevin J. Land, MD; Barbee I. Whitaker, PhD; and Lynne Uhl, MD
International Hemovigilance ........................................................ 94
US Hemovigilance .................................................................... 97
Recipient Hemovigilance in the United States ................................. 98
Blood Donor Hemovigilance in the United States ............................. 102
Conclusion ............................................................................... 105
Key Points ................................................................................ 107
References ............................................................................... 108

BLOOD COLLECTION AND TESTING

5. Allogeneic and Autologous Blood Donor Selection ....................... 111
Debra A. Kessler, RN, MS, and Susan N. Rossmann, MD, PhD
Overview of Blood Donor Screening ............................................ 111
Selection of Allogeneic Blood Donors ........................................... 112
Blood-Center-Defined Donor Eligibility Criteria ............................... 117
Abbreviated DHQ for Frequent Donors ........................................ 119
Recipient-Specific “Designated” or “Directed” Blood Donation ........... 120
Key Points ................................................................................ 121
References ............................................................................... 122
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6. Whole Blood and Apheresis Collections for Blood Components Intended for Transfusion</td>
<td>125</td>
</tr>
<tr>
<td>Stephen J. Wagner, PhD</td>
<td></td>
</tr>
<tr>
<td>Donor Preparation</td>
<td>125</td>
</tr>
<tr>
<td>Blood Collection Process</td>
<td>127</td>
</tr>
<tr>
<td>Adverse Donor Reactions</td>
<td>129</td>
</tr>
<tr>
<td>WB for Component Preparation or Transfusion</td>
<td>131</td>
</tr>
<tr>
<td>Descriptions of Major Blood Components</td>
<td>133</td>
</tr>
<tr>
<td>Blood Component Modification</td>
<td>148</td>
</tr>
<tr>
<td>Quarantine</td>
<td>152</td>
</tr>
<tr>
<td>Labeling</td>
<td>152</td>
</tr>
<tr>
<td>Key Points</td>
<td>153</td>
</tr>
<tr>
<td>References</td>
<td>154</td>
</tr>
<tr>
<td>7. Infectious Disease Screening</td>
<td>161</td>
</tr>
<tr>
<td>Susan L. Stramer, PhD, and Susan A. Galel, MD</td>
<td></td>
</tr>
<tr>
<td>Historical Overview of Blood Donor Screening</td>
<td>161</td>
</tr>
<tr>
<td>Donor Screening Tests</td>
<td>165</td>
</tr>
<tr>
<td>Residual Infectious Risks of Transfusion</td>
<td>177</td>
</tr>
<tr>
<td>Screening for Specific Agents</td>
<td>179</td>
</tr>
<tr>
<td>Pathogen Inactivation Technology</td>
<td>193</td>
</tr>
<tr>
<td>Summary</td>
<td>195</td>
</tr>
<tr>
<td>Key Points</td>
<td>196</td>
</tr>
<tr>
<td>References</td>
<td>197</td>
</tr>
<tr>
<td>8. Molecular Biology and Immunology in Transfusion Medicine</td>
<td>207</td>
</tr>
<tr>
<td>James D. Gorham, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>Analysis of DNA</td>
<td>207</td>
</tr>
<tr>
<td>Analysis of Protein</td>
<td>215</td>
</tr>
<tr>
<td>Basic Immunology</td>
<td>220</td>
</tr>
<tr>
<td>Key Points</td>
<td>227</td>
</tr>
<tr>
<td>References</td>
<td>227</td>
</tr>
<tr>
<td>9. Blood Group Genetics</td>
<td>229</td>
</tr>
<tr>
<td>Christine Lomas-Francis, MSc, FIBMS</td>
<td></td>
</tr>
<tr>
<td>Basic Principles of Genetics</td>
<td>230</td>
</tr>
<tr>
<td>Inheritance of Genetic Traits</td>
<td>239</td>
</tr>
<tr>
<td>Population Genetics</td>
<td>248</td>
</tr>
<tr>
<td>Relationship Testing</td>
<td>250</td>
</tr>
<tr>
<td>Blood Group Gene Mapping</td>
<td>251</td>
</tr>
</tbody>
</table>
10. ABO and Other Carbohydrate Blood Group Systems ........ 265

_Julia S. Westman, PhD, and Martin L. Olsson, MD, PhD_

The ABO System ........................................... 265
The H System ............................................. 278
The Lewis System .......................................... 281
The I Blood Group System and Ii Collection .................. 283
P1PK and Globoside Blood Group Systems and the GLOB Collection ... 286
The FORS Blood Group System ................................ 290
Key Points...................................................... 291
References .................................................... 292

11. The Rh System ........................................... 295

_Gregory A. Denomme, PhD, FCSMLSD_

Historical Perspective ....................................... 295
Terminology .................................................... 298
Rh Locus ....................................................... 299
RHD Genotype ................................................ 299
Antigens ......................................................... 302
Rh Genotyping ................................................ 310
Rhnull Syndrome and RhAG Blood Group System ............. 311
Rh Antibodies ................................................ 311
Technical Considerations for Rh Typing ....................... 312
Key Points...................................................... 314
References .................................................... 314

12. Other Blood Group Systems and Antigens ................. 319

_Jill R. Storry, PhD, FIBMS_

The MNS System ............................................. 319
M (MNS1), N (MNS2), S (MNS3), and s (MNS4) .............. 323
The Lutheran System ....................................... 326
The Kell and KX Systems ................................... 327
The Duffy System ............................................ 330
The Kidd System ............................................. 332
The Diego System ............................................ 334
The Yt System ................................................ 335
The Xg System ................................................ 335
The Scianna System ........................................ 336
The Dombrock System ...................................... 336
The Colton System .......................................... 337
The Landsteiner-Wiener System .............................. 337
Table of Contents

The Chido/Rodgers System ................................................ 338
The Gerbich System ......................................................... 338
The Cromer System ......................................................... 339
The Knops System ......................................................... 339
The Indian System ......................................................... 340
The Ok System .............................................................. 340
The RAPH System .......................................................... 340
The John Milton Hagen System ........................................... 341
The Gill System ............................................................. 341
The RHAG System .......................................................... 341
The FORS System ........................................................... 341
The Jr System ............................................................... 341
The Lan System ............................................................. 342
The Vel System .............................................................. 342
The CD59 System ............................................................ 342
The Augustine System ..................................................... 342
Antigens that Do Not Yet Belong to a Blood Group System ........ 343
Erythroid Phenotypes Caused by Mutations in Transcription
   Factor Genes .............................................................. 344
Key Points ................................................................. 345
References ................................................................. 345

13. Identification of Antibodies to Red Cell Antigens ............. 349
   Janis R. Hamilton, MS, MT(ASCP)SBB, and
   Debra J. Bailey, MT(ASCP)SBB
   Basic Concepts in Red Cell Antigen Expression .................. 350
   Initial Antibody Identification Considerations .................... 351
   Basic Antibody Identification ....................................... 353
   Complex Antibody Identification .................................... 359
   Selected Procedures ................................................... 371
   Considerations Following Antibody Identification ............... 377
   Immunohematology Reference Laboratories ....................... 380
   Key Points .............................................................. 381
   References .............................................................. 382
   Suggested Readings .................................................... 384

14. The Positive Direct Antiglobulin Test and
   Immune-Mediated Hemolysis ........................................... 385
   Regina M. Leger, MSQA, MT(ASCP)SBB, CMQ/OE(ASQ), and
   P. Dayand Borge Jr, MD, PhD
   The DAT ................................................................. 386
   Autoimmune Hemolytic Anemia ....................................... 391
   Drug-Induced Immune Hemolytic Anemia ........................... 401
   Key Points .............................................................. 405
   References .............................................................. 406
   Appendix 14-1. Drugs Associated with Immune Hemolytic Anemia . 409
15. Platelet and Granulocyte Antigens and Antibodies ........... 413
   Ralph R. Vassallo, MD, FACP, and
   Brian R. Curtis, PhD, D(ABMLI), MT(ASCP)SBB
   Platelet Antigens and Antibodies .................................. 413
   Granulocyte Antigens and Antibodies ............................... 425
   Key Points ..................................................................... 429
   References .................................................................... 429

16. The HLA System ......................................................... 435
   Arthur B. Eisenbrey III, MD, PhD, and Patricia M. Kopko, MD
   Biochemistry, Tissue Distribution, and Structure ...................... 436
   Genetics of the MHC .................................................... 440
   Identification of HLA Antigens and Alleles ............................. 444
   Crossmatching and Detection of HLA Antibodies ..................... 447
   The HLA System and Transfusion ....................................... 447
   HLA Testing and Transplantation ....................................... 450
   Other Clinically Significant Aspects of HLA ......................... 452
   Summary .................................................................... 453
   Key Points ..................................................................... 454
   References .................................................................... 454

---

17. Transfusion-Service-Related Activities: Pretransfusion
    Testing and Storage, Monitoring, Processing, Distribution, and Inventory Management of
    Blood Components ...................................................... 457
   Sarah K. Harm, MD, and Nancy M. Dunbar, MD
   Samples and Requests ..................................................... 457
   Pretransfusion Testing of Recipient Blood ............................. 458
   Blood and Blood Component Storage and Monitoring .............. 463
   Pretransfusion Processing ................................................. 471
   Distribution .................................................................. 474
   Issuing of Components .................................................... 476
   Inventory Management .................................................... 479
   Key Points ..................................................................... 481
   References .................................................................... 482
   Appendix 17-1. Sources of False-Positive Results in Antiglobulin
                  Testing ................................................................. 485
   Appendix 17-2. Sources of False-Negative Results in Antiglobulin
                  Testing ................................................................. 486
   Appendix 17-3. Causes of Positive Pretransfusion Test Results .... 487
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>18.</td>
<td>Administration of Blood Components</td>
<td>489</td>
</tr>
<tr>
<td></td>
<td>Melanie Jorgenson, RN, BSN, LSSGB</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Events and Considerations Before Dispensing Components</td>
<td>489</td>
</tr>
<tr>
<td></td>
<td>Blood Component Transportation and Dispensing</td>
<td>494</td>
</tr>
<tr>
<td></td>
<td>Administration</td>
<td>495</td>
</tr>
<tr>
<td></td>
<td>Documentation of the Transfusion</td>
<td>499</td>
</tr>
<tr>
<td></td>
<td>Unique Transfusion Settings</td>
<td>500</td>
</tr>
<tr>
<td></td>
<td>Conclusions</td>
<td>501</td>
</tr>
<tr>
<td></td>
<td>Key Points</td>
<td>501</td>
</tr>
<tr>
<td></td>
<td>References</td>
<td>502</td>
</tr>
<tr>
<td>19.</td>
<td>Hemotherapy Decisions and Their Outcomes</td>
<td>505</td>
</tr>
<tr>
<td></td>
<td>Richard M. Kaufman, MD, and Nadine Shehata, MD, FRCP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Red Blood Cell Transfusion</td>
<td>505</td>
</tr>
<tr>
<td></td>
<td>Platelet Transfusion</td>
<td>511</td>
</tr>
<tr>
<td></td>
<td>Plasma Transfusion</td>
<td>516</td>
</tr>
<tr>
<td></td>
<td>Cryoprecipitate Transfusion</td>
<td>518</td>
</tr>
<tr>
<td></td>
<td>Granulocyte Transfusion</td>
<td>519</td>
</tr>
<tr>
<td></td>
<td>Key Points</td>
<td>520</td>
</tr>
<tr>
<td></td>
<td>References</td>
<td>521</td>
</tr>
<tr>
<td>20.</td>
<td>Patient Blood Management</td>
<td>527</td>
</tr>
<tr>
<td></td>
<td>Kathleen E. Puca, MD, MT(ASCP)SBB</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Definition and Scope of Patient Blood Management</td>
<td>527</td>
</tr>
<tr>
<td></td>
<td>The Rationale for PBM</td>
<td>528</td>
</tr>
<tr>
<td></td>
<td>Basic Elements of a PBM Program</td>
<td>529</td>
</tr>
<tr>
<td></td>
<td>Key Points</td>
<td>540</td>
</tr>
<tr>
<td></td>
<td>References</td>
<td>540</td>
</tr>
<tr>
<td></td>
<td>Appendix 20-1. Pharmacologic Therapies for Supporting Patient Blood Management</td>
<td>546</td>
</tr>
<tr>
<td></td>
<td>Appendix 20-2. Responsibilities for Activity Levels 1, 2, and 3 PBM Programs</td>
<td>555</td>
</tr>
<tr>
<td>21.</td>
<td>Approaches to Blood Utilization Auditing</td>
<td>557</td>
</tr>
<tr>
<td></td>
<td>Irina Maramica, MD, PhD, MBA, and Ira A. Shulman, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Auditing Process</td>
<td>558</td>
</tr>
<tr>
<td></td>
<td>Types of Blood Utilization Review</td>
<td>559</td>
</tr>
<tr>
<td></td>
<td>Blood Utilization Review of Transfusions to High-Risk Patients</td>
<td>562</td>
</tr>
<tr>
<td></td>
<td>The Role of a Computerized Provider Order Entry System in Blood Utilization Review</td>
<td>563</td>
</tr>
<tr>
<td></td>
<td>Use of “Big Data” to Assess Performance and Progress Measures in Transfusion Medicine</td>
<td>564</td>
</tr>
<tr>
<td></td>
<td>Key Points</td>
<td>565</td>
</tr>
<tr>
<td></td>
<td>References</td>
<td>566</td>
</tr>
</tbody>
</table>
22. Noninfectious Complications of Blood Transfusion ........ 569

William J. Savage, MD, PhD, and Eldad A. Hod, MD

Hemovigilance ......................................................... 569
Recognition and Evaluation of a Suspected Transfusion Reaction ...... 569
Acute or Immediate Transfusion Reactions .......................... 576
Delayed Transfusion Reactions .................................... 588
Fatality Reporting Requirements ................................... 592
Key Points .............................................................. 593
References ............................................................. 594

SPECIAL PATIENTS AND SITUATIONS

23. Perinatal Issues in Transfusion Practice ................. 599

Meghan Delaney, DO, MPH; Annika M. Svensson, MD, PhD;
Lani Lieberman, MD, MSc

Hemolytic Disease of the Fetus and Newborn .......................... 599
Thrombocytopenia .................................................. 605
Key Points .............................................................. 608
References ............................................................. 608

24. Neonatal and Pediatric Transfusion Practice ............. 613

Edward C.C. Wong, MD, and Rowena C. Punzalan, MD

Transfusion in Infants Younger than 4 Months .......................... 613
Transfusion in Infants Older than 4 Months and Children ............ 628
Prevention of Adverse Effects of Transfusion in the Pediatric
Population ........................................................... 632
Key Points .............................................................. 634
References ............................................................. 634

25. Therapeutic Apheresis .............................. 641

Chester Andrzejewski Jr, PhD, MD, and Robertson D. Davenport, MD

General Principles .................................................... 641
Device Modalities .................................................... 642
Patient Evaluation and Management ................................... 643
Vascular Access ....................................................... 645
Anticoagulation ....................................................... 646
Adverse Effects ....................................................... 646
Therapeutic Apheresis Indications ................................... 648
Therapeutic Apheresis Procedure Documentation, Payment, and
Provider Credentialing ............................................... 663
Key Points .............................................................. 663
References ............................................................. 664
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>26. The Collection and Processing of Hematopoietic Progenitor Cells</td>
<td>667</td>
</tr>
<tr>
<td>Eapen K. Jacob, MD, and Scott A. Koepsell, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>Clinical Utility</td>
<td>667</td>
</tr>
<tr>
<td>Determination of Graft Source</td>
<td>670</td>
</tr>
<tr>
<td>Collection/Sources of HPCs</td>
<td>672</td>
</tr>
<tr>
<td>Processing HPCs</td>
<td>674</td>
</tr>
<tr>
<td>Specialized Cell-Processing Methods</td>
<td>675</td>
</tr>
<tr>
<td>Cryopreservation</td>
<td>676</td>
</tr>
<tr>
<td>QC</td>
<td>676</td>
</tr>
<tr>
<td>Shipping and Transporting HPC Cellular Products</td>
<td>677</td>
</tr>
<tr>
<td>Patient Care</td>
<td>677</td>
</tr>
<tr>
<td>Other Regulatory Considerations</td>
<td>678</td>
</tr>
<tr>
<td>Conclusion</td>
<td>678</td>
</tr>
<tr>
<td>Key Points</td>
<td>679</td>
</tr>
<tr>
<td>References</td>
<td>679</td>
</tr>
<tr>
<td>27. Transfusion Support for Hematopoietic Stem Cell Transplant Recipients</td>
<td>683</td>
</tr>
<tr>
<td>Melissa M. Cushing, MD, and Jeanne E. Hendrickson, MD</td>
<td></td>
</tr>
<tr>
<td>ABO- and Non-ABO-Red-Cell-Antigen-Incompatible Transplantation</td>
<td>684</td>
</tr>
<tr>
<td>Blood Component Considerations</td>
<td>685</td>
</tr>
<tr>
<td>Neutropenic Patients with Infections Unresponsive to Antimicrobial Therapy</td>
<td>689</td>
</tr>
<tr>
<td>Special Processing of Blood Components for Recipients of HSCT</td>
<td>689</td>
</tr>
<tr>
<td>Special Considerations for Transfusing Pediatric HSCT Recipients</td>
<td>690</td>
</tr>
<tr>
<td>Information Portability for HSCT Recipients</td>
<td>690</td>
</tr>
<tr>
<td>Key Points</td>
<td>691</td>
</tr>
<tr>
<td>References</td>
<td>691</td>
</tr>
<tr>
<td>28. Human Tissue Allografts and the Hospital Transfusion Service</td>
<td>695</td>
</tr>
<tr>
<td>Annette J. Schluteer, MD, PhD; Cassandra D. Josephson, MD; and Scott A. Brubaker, CTBS</td>
<td></td>
</tr>
<tr>
<td>Tissue Donation and Transplantation</td>
<td>695</td>
</tr>
<tr>
<td>Federal Regulations, State Laws, and Professional Standards</td>
<td>700</td>
</tr>
<tr>
<td>Hospital Tissue Services</td>
<td>701</td>
</tr>
<tr>
<td>Key Points</td>
<td>706</td>
</tr>
<tr>
<td>References</td>
<td>707</td>
</tr>
<tr>
<td>Index</td>
<td>709</td>
</tr>
</tbody>
</table>
Contents on USB Flash Card

METHODS

1. General Laboratory Methods—Introduction
   Method 1-1. Shipping Hazardous Materials
   Method 1-2. Monitoring Temperature During Shipment of Blood
   Method 1-3. Treating Incompletely Clotted Specimens
   Method 1-4. Solution Preparation Procedure
   Method 1-5. Serum Dilution Procedure
   Method 1-6. Dilution of Percentage Solutions Procedure
   Method 1-7. Preparing a 3% Red Cell Suspension
   Method 1-8. Preparing and Using Phosphate Buffer
   Method 1-9. Reading and Grading Tube Agglutination

2. Red Cell Typing Methods—Introduction
   Method 2-1. Determining ABO Group of Red Cells—Slide Test
   Method 2-2. Determining ABO Group of Red Cells and Serum—Tube Test
   Method 2-3. Determining ABO Group of Red Cells and Serum—Microplate Test
   Method 2-4. Initial Investigation of ABO Grouping Discrepancies Procedure
   Method 2-5. Detecting Weak A and B Antigens and Antibodies by Cold Temperature Enhancement
   Method 2-6. Confirming Weak A and B Antigens Using Enzyme-Treated Red Cells
   Method 2-7. Confirming Weak A or B Subgroup by Adsorption and Elution
   Method 2-8. Testing Saliva for A, B, H, Le^a, and Le^b Antigens
   Method 2-9. Confirming Anti-A_1 in an A_2 or Weak A Subgroup
   Method 2-10. Resolving ABO Discrepancies Caused by Unexpected Alloantibodies
   Method 2-11. Determining Serum Group Without Centrifugation
   Method 2-12. Determining Rh(D) Type—Slide Test
   Method 2-13. Determining Rh(D) Type—Tube Test
   Method 2-14. Determining Rh(D) Type—Microplate Test
   Method 2-15. Testing for Weak D
   Method 2-16. Preparing and Using Lectins
   Method 2-17. Removing Autoantibody by Warm Saline Washes
   Method 2-18. Using Sulfhydryl Reagents to Disperse Autoagglutination
   Method 2-19. Using Gentle Heat Elution to Test Red Cells with a Positive DAT Result
   Method 2-20. Dissociating IgG by Chloroquine for Antigen Testing of Red Cells with a Positive DAT Result
   Method 2-21. Using Acid Glycine/EDTA to Remove Antibodies from Red Cells
   Method 2-22. Separating Transfused from Autologous Red Cells by Simple Centrifugation
   Method 2-23. Separating Transfused from Autologous Red Cells in Patients with Hemoglobin S Disease
Table of Contents

3. Antibody Detection, Identification, and Compatibility Testing—Introduction

   Method 3-1. Using Immediate-Spin Compatibility Testing to Demonstrate ABO Incompatibility
   Method 3-2. Saline Indirect Antiglobulin Test Procedure
   Method 3-3. Albumin or LISS-Additive Indirect Antiglobulin Test Procedure
   Method 3-4. LISS-Suspension Indirect Antiglobulin Test Procedure
   Method 3-5. PEG Indirect Antiglobulin Test Procedure
   Method 3-6. Prewarming Procedure
   Method 3-7. Detecting Antibodies in the Presence of Rouleaux—Saline Replacement
   Method 3-8. Preparing Ficin Enzyme Stock, 1% w/v
   Method 3-9. Preparing Papain Enzyme Stock, 1% w/v
   Method 3-10. Standardizing Enzyme Procedures
   Method 3-11. Evaluating Enzyme-Treated Red Cells
   Method 3-12. One-Stage Enzyme Procedure
   Method 3-13. Two-Stage Enzyme Procedure
   Method 3-14. Performing a Direct Antiglobulin Test
   Method 3-15. Antibody Titration Procedure
   Method 3-16. Using Sulphydryl Reagents to Distinguish IgM from IgG Antibodies
   Method 3-17. Using Plasma Inhibition to Distinguish Anti-Ch and -Rg from Other Antibodies with Similar Characteristics
   Method 3-18. Treating Red Cells Using DTT or AET
   Method 3-19. Neutralizing Anti-Sd^a with Urine
   Method 3-20. Adsorption Procedure
   Method 3-21. Using the American Rare Donor Program

4. Investigation of a Positive DAT Result—Introduction

   Method 4-1. Cold-Acid Elution Procedure
   Method 4-2. Glycine-HCl/EDTA Elution Procedure
   Method 4-3. Heat Elution Procedure
   Method 4-4. Lui Freeze-Thaw Elution Procedure
   Method 4-5. Cold Autoadsorption Procedure
   Method 4-6. Determining the Specificity of Cold-Reactive Autoagglutinins
   Method 4-7. Cold Agglutinin Titer Procedure
   Method 4-8. Adsorbing Warm-Reactive Autoantibodies Using Autologous Red Cells
   Method 4-9. Adsorbing Warm-Reactive Autoantibodies Using Allogeneic Red Cells
   Method 4-10. Polyethylene Glycol Adsorption Procedure
   Method 4-11. Performing the Donath-Landsteiner Test
   Method 4-12. Detecting Drug Antibodies by Testing Drug-Treated Red Cells
5. Hemolytic Disease of the Fetus and Newborn—Introduction

Method 5-1. Testing for Fetomaternal Hemorrhage—The Rosette Test
Method 5-2. Testing for Fetomaternal Hemorrhage—Modified Kleihauer-Betke Test
Method 5-3. Using Antibody Titration Studies to Assist in Early Detection of Hemolytic Disease of the Fetus and Newborn

6. Blood Collection, Component Preparation, and Storage—Introduction

Method 6-1. Screening Female Donors for Acceptable Hemoglobin Level—Copper Sulfate Method
Method 6-2. Preparing the Donor’s Arm for Blood Collection
Method 6-3. Collecting Blood and Samples for Processing and Testing
Method 6-4. Preparing Red Blood Cells from Whole Blood
Method 6-5. Preparing Prestorage Red Blood Cells Leukocytes Reduced from Whole Blood
Method 6-6. Using High-Concentration Glycerol to Cryopreserve Red Cells—Meryman Method
Method 6-7. Using High-Concentration Glycerol to Cryopreserve Red Cells—Valeri Method
Method 6-8. Checking the Adequacy of Deglycerolization of Red Blood Cells
Method 6-9. Preparing Fresh Frozen Plasma from Whole Blood
Method 6-10. Preparing Cryoprecipitated AHF from Whole Blood
Method 6-11. Thawing and Pooling Cryoprecipitated AHF
Method 6-12. Preparing Platelets from Whole Blood
Method 6-13. Removing Plasma from Platelets (Volume Reduction)

7. Transplantation of Cells and Tissue—Introduction

Method 7-1. Infusing Cryopreserved Hematopoietic Cells
Method 7-2. Processing Umbilical Cord Blood
Method 7-3. Investigating Adverse Events and Infections Following Tissue Allograft Use

8. Quality Control Methods—Introduction

Method 8-1. Validating Copper Sulfate Solution
Method 8-2. Calibrating Liquid-in-Glass Laboratory Thermometers
Method 8-3. Calibrating Electronic Oral Thermometers
Method 8-4. Testing Refrigerator Alarms
Method 8-5. Testing Freezer Alarms
Method 8-6. Calibrating Centrifuges for Platelet Separation
Method 8-7. Calibrating a Serologic Centrifuge for Immediate Agglutination Testing
Method 8-8. Calibrating a Serologic Centrifuge for Washing and Antiglobulin Testing
Method 8-10. Monitoring Cell Counts of Apheresis Components

APPENDICES

Appendix 1. Normal Values in Adults
Appendix 2. Selected Normal Values in Children
Appendix 3. Typical Normal Values in Tests of Hemostasis and Coagulation (Adults)
Appendix 4. Coagulation Factor Values in Platelet Concentrates
Appendix 5. Approximate Normal Values for Red Cell, Plasma, and Blood Volumes
Appendix 6. Blood Group Antigens Assigned to Systems
Appendix 7. Examples of Gene, Antigen, and Phenotype Symbols in Conventional and International Society of Blood Transfusion Terminology
Appendix 8. Examples of Correct and Incorrect Terminology
Appendix 9. Distribution of ABO/Rh Phenotypes by Race or Ethnicity
Appendix 10. Example of a Maximum Surgical Blood Order Schedule